Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Nivolumab & Gastroesophageal junction cancer (GEJ)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Concerning Nivolumab & Gastroesophageal junction cancer (GEJ), the pase III trial NCT02743494 showed, that among patients with resected esophageal or Gastroesophageal junction cancer (GEJ) who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo (1).

Nivolumab is approved by both FDA and EMA for certain settings in gastroesophageal junction (GEJ) cancer: as adjuvant therapy after resection and chemoradiotherapy for esophageal/GEJ cancer wit…

References (Sources)

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Kelly et al. 2021 N Engl J Med 384: 1191-1203
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy
Pelosof et al. 2021
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Heymach et al. 2018
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease
Horiba et al. 2022 Clin Cancer Res 28(24): 5244-5248
Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme
Soni et al. 2021 Future Oncology 17: 3163-3174
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Kang et al. 2017 Lancet. 390: 2461-2471

AI Chat

7/1/2026

Chat with our artificial intelligence: